The University of Southampton
University of Southampton Institutional Repository

The expression and regulation of ADAM33, a novel asthma susceptibility gene, during myofibrolast differentiation

The expression and regulation of ADAM33, a novel asthma susceptibility gene, during myofibrolast differentiation
The expression and regulation of ADAM33, a novel asthma susceptibility gene, during myofibrolast differentiation

To test the hypothesis that TGFβ may promote the ability of fibroblasts to differentiate into smooth muscle cells in asthma, the expression of five smooth muscle associated genes was examined.  Heavy Chain Myosin, Calponin and Desmin were all shown to be upregulated to a greater extent (p<0.05) in asthmatic (n=7) primary airway fibroblast cultures than in healthy control cells (n=6).  α Smooth Muscle Actin and γ Actin were upregulated maximally at a lower dose of TGFβ in asthmatic cells compared with healthy cells (p<0.05).  Alongside the upregulation of mRNA, an increase in protein for four of these smooth muscle marker genes was detected in TGFβ treated cells by immunohistochemistry.  Desmin protein however, was not detected at the protein level and hence a bona fide phenotype switch from fibroblast to smooth muscle cell was not achieved.

To test the hypothesis that ADAM33 is involved in fibroblast differentiation, the effect of TGFβ on ADAM33 expression was investigated.  In association with the switch towards a myofibroblast phenotype, global ADAM33 mRNA expression as well as that of individual ADAM33 splice variants was down-regulated in a dose dependent manner by TGFβ.  To measure ADAM33 protein expression, antibodies were generated by the immunisation of four rabbits and two chickens with ADAM33 specific peptide sequences.  These antibodies were shown to be active against their respective immunising peptides but failed to detect full length ADAM33.  However, a commercially available anti-ADAM33 antibody preparation was found to specifically detect ADAM33.  ADAM33 protein expression was shown to be down-regulated upon TGFβ treatment as detected by immunofluorescent staining.  In addition products of ADAM33 degradation were shown to accumulate upon TGFβ treatment in primary cells as well as a recombinant model, as detected by western blot.

University of Southampton
Wicks, James
6b178ed1-5c0c-448c-97f1-5c505d1e530a
Wicks, James
6b178ed1-5c0c-448c-97f1-5c505d1e530a

Wicks, James (2005) The expression and regulation of ADAM33, a novel asthma susceptibility gene, during myofibrolast differentiation. University of Southampton, Doctoral Thesis.

Record type: Thesis (Doctoral)

Abstract

To test the hypothesis that TGFβ may promote the ability of fibroblasts to differentiate into smooth muscle cells in asthma, the expression of five smooth muscle associated genes was examined.  Heavy Chain Myosin, Calponin and Desmin were all shown to be upregulated to a greater extent (p<0.05) in asthmatic (n=7) primary airway fibroblast cultures than in healthy control cells (n=6).  α Smooth Muscle Actin and γ Actin were upregulated maximally at a lower dose of TGFβ in asthmatic cells compared with healthy cells (p<0.05).  Alongside the upregulation of mRNA, an increase in protein for four of these smooth muscle marker genes was detected in TGFβ treated cells by immunohistochemistry.  Desmin protein however, was not detected at the protein level and hence a bona fide phenotype switch from fibroblast to smooth muscle cell was not achieved.

To test the hypothesis that ADAM33 is involved in fibroblast differentiation, the effect of TGFβ on ADAM33 expression was investigated.  In association with the switch towards a myofibroblast phenotype, global ADAM33 mRNA expression as well as that of individual ADAM33 splice variants was down-regulated in a dose dependent manner by TGFβ.  To measure ADAM33 protein expression, antibodies were generated by the immunisation of four rabbits and two chickens with ADAM33 specific peptide sequences.  These antibodies were shown to be active against their respective immunising peptides but failed to detect full length ADAM33.  However, a commercially available anti-ADAM33 antibody preparation was found to specifically detect ADAM33.  ADAM33 protein expression was shown to be down-regulated upon TGFβ treatment as detected by immunofluorescent staining.  In addition products of ADAM33 degradation were shown to accumulate upon TGFβ treatment in primary cells as well as a recombinant model, as detected by western blot.

Text
1020550.pdf - Version of Record
Available under License University of Southampton Thesis Licence.
Download (5MB)

More information

Published date: 2005

Identifiers

Local EPrints ID: 465965
URI: http://eprints.soton.ac.uk/id/eprint/465965
PURE UUID: 1f9a806b-2870-4023-a5e3-68d33502d903

Catalogue record

Date deposited: 05 Jul 2022 03:48
Last modified: 16 Mar 2024 20:27

Export record

Contributors

Author: James Wicks

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×